Long-term sedation with propofol 60 mg ml-1 vs. propofol 10 mg ml-1 in critically ill, mechanically ventilated patients

Acta Anaesthesiologica Scandinavica

Volumn 48, Issue 3, 2004, Pages 302-307

  Knibbe, Catherijne A J ^a   Naber, H ^a   Aarts, L P H J ^a   Kuks, P F M ^a   Danhof, M ^b  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Critical care; Lipids; Nutrition; Propofol; Sedation; Triglyceride

Indexed keywords

LIPID; MIDAZOLAM; PROPOFOL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CRITICAL ILLNESS; DOSE RESPONSE; DRUG EFFICACY; DRUG INFUSION; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LONG TERM CARE; MALE; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SCORING SYSTEM; SEDATION; TREATMENT FAILURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ANESTHETICS, INTRAVENOUS; CONSCIOUS SEDATION; CRITICAL ILLNESS; DRUG COMBINATIONS; ENTERAL NUTRITION; FAT EMULSIONS, INTRAVENOUS; HUMANS; INFUSIONS, INTRAVENOUS; METABOLIC CLEARANCE RATE; MIDDLE AGED; PHOSPHOLIPIDS; PROPOFOL; PROSPECTIVE STUDIES; RESPIRATION, ARTIFICIAL; SORBITOL; TIME FACTORS; TRIGLYCERIDES;

EID: 1542376645     PISSN: 00015172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-6576.2004.0339.x     Document Type: Article

References (35)

1. Young C, Knudsen N, Hilton A, Reves JG. Sedation in the intensive care unit. Crit Care Med 2000; 28: 854-66.
2. Murdoch S., Cohen A. Intensive care sedation, a review of current British practice. Intensive Care Med 2000; 26: 922-8.
3. Bryson HM, Fulton BR, Faulds D. Propofol. An update of its use in anaesthesia and conscious sedation. Drugs 1995; 50: 513-59.
4. Fulton B, Sorkin EM. Propofol. An overview of its pharmacology and a review of its clinical efficacy in intensive care sedation. Drugs, 1995; 50: 636-57.
5. Carrasco G, Molina R, Costa J, Soler J-M, Cabre L. Propofol vs midazolam in short-, medium-, and long-term sedation of critically ill patients. A cost-benefit analysis. Chest 1993; 103: 557-64.
6. Barrientos-Vega R, Sanchez-Soria MM, Morales-Garcia C et al. Prolonged sedation of critically ill patients with midazolam or propofol: impact on weaning and costs. Crit Care Med 1997; 25: 33-40.
7. Sanchez-Izuierdo-Riera JA, Caballero-Cubedo RE, Perez-Vela JL et al. Propofol versus midazolam: safety and efficacy for sedating the severe trauma patient. Anesth Analg 1998; 86: 1219-24.
8. Bailie GR, Cockshott ID, Douglas EJ, Bowles BJ. Pharmacokinetics of propofol during and after long term continuous infusion for maintenance of sedation in ICU patients. Br J Anaesth 1992; 68: 486-91.
9. Beller JP, Pottecher T, Lugnier A, Mangin P, Otteni JC. Prolonged sedation with propofol in ICU patients: recovery and blood concentration changes during periodic interruptions in infusion. Br J Anaesth 1988; 61: 583-8.
10. Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000; 342: 1471-7.
11. Knibbe CAJ, Koster VS, Aarts LPHJ, Langemeijer JJM, Danhof M. Pilot study in humans on the pharmacokinetics and safety of Propofol 6%. Pharm World Sci 1999; 21: 239-40.
12. Knibbe CAJ, Voortman HJ, Aarts LPHJ et al. Pharmacokinetics, induction of anaesthesia and safety characteristics of Propofol 6% versus Propofol 1% and Diprivan®-10 after bolus injection. Br J Clin Pharmacol 1999; 47: 653-60.
13. Knibbe CAJ, Aarts LPHJ, Kuks PFM et al. Pharmacokinetics and pharmacodynamics of Propofol 6% versus Propofol 1% and Diprivan®-10 for short-term sedation following coronary artery bypass surgery. Eur J Clin Pharmacol 2000; 56: 89-95.
14. Knibbe CAJ, Melenhorst-de Jong G, Mestrom M et al. Population pharmacokinetics of Propofol 6% for short-term sedation in paediatric patients following cardiac surgery. Br J Clin Pharmacol 2002; 54: 154-422.
15. Cox EH, Knibbe CAJ, Koster VS et al. Influence of different fat emulsion-based intravenous formulations on the pharmacokinetics and pharmacodynamics of propofol. Pharm Res 1998; 15: 442-8.
16. Knibbe CAJ, Zuideveld KP, DeJongh J, Kuks PFM, Aarts LPHJ, Danhof M. Population pharmacokinetic and pharmacodynamic modelling of propofol for long term sedation in critically ill patients. A comparison between Propofol 6% and Propofol 1%. Clin Pharmacol Ther 2002; 72 (6): 670-84.
17. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II, a severity of disease classification system. Crit Care Med 1985; 13: 818-29.
18. Buckley PM. Propofol in patients needing long-term sedation in intensive care: an assessment of the development of tolerance. Int Care Med 1997; 23: 969-74.
19. Ramsay MAE, Savege TM, Simpson BRJ, Goodwin R. Controlled sedation with alphaxalone-alphadolone. BMJ 1974; 2: 656-9.
20. Knibbe CAJ, Koster VS, Deneer VHM, Stuurman RM, Kuks PFM, Lange R. Determination of propofol in low Volume samples by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl 1998; 706: 305-10.
21. Koster VS, Maring JG, Knibbe CAJ et al. Propofol 6%. preparation and stability of a new formulation of propofol. Eur J Hospital Pharmacy 2000; 6: 92-6.
22. Chamorro C, Latorre de FJ, Montero A et al. Comparative study of propofol versus midazolam in the sedation of critically ill patients: Results of a prospective, randomized, multicenter trial. Crit Care Med 2001; 24: 932-9.
23. Swart EL, Strack van Schijndel RJM, van Loenen AC, Thijs LG. Continuous infusion of lorazepam versus midazolam in the intensive care unit: sedation with lorazepam is easier to manage and is more cost-effective. Crit Care Med 1999; 27: 1461-5.
24. Eddleston JM, Shelly MP. The effect on serum lipid concentrations of a prolonged infusion of propofol - hypertriglyceridaemia associated with propofol administration. Int Care Med 1991; 17: 424-6.
25. McLeod G, Dick J, Wallis C, Patterson A, Cox C, Colvin J. Propofol 2% in critically ill patients: Effects on lipids. Crit Care Med 1997; 25: 1976-81.
26. Ewart MC, Yau KW, Morgan M. 2% propofol for sedation in the intensive care unit. Anaesthesia 1992; 47: 146-8.
27. Lindholm M. Critically ill patients and fat emulsions. Minerva Anestesiologica 1992; 58: 875-9.
28. Mateu J, Barrachina F. Hypertriglyceridaemia associated with propofol sedation in critically ill patients. Int Care Med 1996; 22: 834-5.
29. Mateu-de Antonio J, Barrachina F. Propofol infusion and nutritional support. Am J Health Syst Pharm 1997; 54: 2515-6.
30. Roth MS, Martin AB, Katz JA. Nutritional implications of prolonged propofol use. Am J Health-Syst Pharm 1997; 54: 694-5.
31. Zamacona MK, Suarez E, Garcia E, Aguirre C, Calvo R. The significance of lipoproteins in serum binding variations of propofol. Anesth Analg 1998; 87: 1147-51.
32. Valente JF, Anderson GL, Branson RD, Johnson DJ, Davis KJ, Porembka DT. Disadvantages of prolonged propofol sedation in the critical care unit. Crit Care Med 1994; 22: 710-2.
33. Zacher AN, Zornow MH, Evan G. Drug contamination from opening glass ampoules. Anesthesiology 1991; 73: 893-5.
34. Bennett SN, McNeil MM, Bland LA et al. Postoperative infections traced to contamination of an intravenous anaesthetic propofol. N Engl J Med 1995; 333: 147-54.
35. Graystone S, Wells MF, Farrell DJ. Do intensive care drug infusions support microbial growth? Anaesth Int Care 1997; 25: 640-2.